Dataset from An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal
pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib
in patients with moderate hepatic impairment, for the purpose of providing recommendations to
guide the initial dose and dose titration in this patient population.